

## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: bpgoffice@wignet.com http://www.wignet.com

## ESPS JOURNAL EDITOR-IN-CHIEF'S REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 20154

Title: Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical

and nutraceutical agents

Journal Editor-in-Chief (Associate Editor): Bei-Cheng Sun

Country: China

**Editorial Director:** Jin-Lei Wang

**Date sent for review: 2015-11-09 16:14** 

Date reviewed: 2015-11-10 14:00

ACADEMIC CONTENT	LANGUAGE QUALITY	CONCLUSION
EVALUATION	EVALUATION	
[ Y] Grade A: Excellent	[Y] Grade A: Priority publishing	[Y] Accept
[ ] Grade B: Very good	[ ] Grade B: Minor language polishing	[ ] High priority for
[ ] Grade C: Good	[ ] Grade C: A great deal of	publication
[ ] Grade D: Fair	language polishing	[ ] Revision
[ ] Grade E: Poor	[ ] Grade D: Rejected	[ ] Rejection

## JOURNAL EDITOR-IN-CHIEF (ASSOCIATE EDITOR) COMMENTS TO AUTHORS

Liver cancer is mainly driven by HBV and HCV infections, which account for 80% of cases, but in the near future obesity is likely to become the leading factor. Non-alcoholic fatty liver disease (NAFLD) and its more aggressive manifestation, non-alcoholic steatohepatitis (NASH), is emerging as the primary driving force behind this growth. Thus, the molecular mechanisms underlying the pathogenes of obesity-related hepatocarcinogenesis is very important. In this review paper, the author summarize recent evidence from experimental and clinical studies using either nutraceutical or pharmaceutical agents, and suggest that nutraceutical and pharmaceutical approaches targeting metabolic abnormalities might be a promising strategy to prevent the development of obesity-related HCC. This is an interesting review paper, and valuable to be published in World Journal of Gastroenterology.